ASCO 2023 | Elucidating novel targets in solid tumors for CAR T-cell therapy

Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, comments on challenges in developing CAR T-cell therapies for solid tumors. Finding safe and efficacious targets remain an issue, where established receptors such as HER2 can cause severe toxicity, unless novel agents such as TAC T-cells are developed. Additional promising targets include claudin 18.2, which has reduced toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.